A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

Summary

This study will evaluate the efficacy and safety of ALKS 5461.

Timeline

Start

2014-05

Primary completion

2015-12

Completion

2015-12

Outcome

Missed primary endpoint

registry analysis (superiority test); ALKS 5461 2mg/2mg vs Placebo; p = 0.782; Least square means difference -0.3 (95% CI -2.1 to 1.6); NCT02158546 ↗

Drugs

Indications